Professor of Radiation Oncology, University Alabama
Radiation Oncology
Dr. Ruby F. Meredith, MD
|
|
Give Review
Ruby F. Meredith works in the field of Radiation Oncology. He researched medicine at The Ohio State University College of Medicine. He over the years received 3 awards: "America's Top Doctors", "America's Top Doctors for Cancer" and "Whos Who in Medicine and Healthcare". Dr. Ruby F. Meredith is a published doctor. He has 101 papers published. The most current publication "Phase II study of dual 131I-labeled monoclonal antibody therapy with interferon in patients with metastatic colorectal cancer." He accepts all Medicare patients.
Publications
- Dose Escalation and Dosimetry of First-in-Human α Radioimmunotherapy with 212Pb-TCMC-Trastuzumab.
- Pazopanib Combined with Radiation: In Vivo Model of Interaction.
- Pharmacokinetics and imaging of 212Pb-TCMC-trastuzumab after intraperitoneal administration in ovarian cancer patients.
- Predictors of long-term outcome from intraperitoneal radioimmunotherapy for ovarian cancer.
- Biodistribution and dosimetry of In-111/Y-90-HuCC49ΔCh2 (IDEC-159) in patients with metastatic colorectal adenocarcinoma.
- Renal dosimetry.
- Pilot trial of preoperative (neoadjuvant) letrozole in combination with bevacizumab in postmenopausal women with newly diagnosed estrogen receptor- or progesterone rec...
- MIRD Pamphlet No. 22 (abridged): radiobiology and dosimetry of alpha-particle emitters for targeted radionuclide therapy.
- Dosimetric factors associated with long-term dysphagia after definitive radiotherapy for squamous cell carcinoma of the head and neck.
- Impact of rituximab treatment on (90)Y-ibritumomab dosimetry for patients with non-Hodgkin lymphoma.
- Margin on gross tumor volume and risk of local recurrence in head-and-neck cancer.
- NCCN clinical practice guidelines in oncology: multiple myeloma.
- Mucositis-related morbidity and resource utilization in head and neck cancer patients receiving radiation therapy with or without chemotherapy.
- MIRD dose estimate report No. 20: radiation absorbed-dose estimates for 111In- and 90Y-ibritumomab tiuxetan.
- Factors associated with long-term dysphagia after definitive radiotherapy for locally advanced head-and-neck cancer.
- Dose optimization of breast balloon brachytherapy using a stepping 192Ir HDR source.
- Cancer of the tonsil presenting as central nervous system metastasis: A case report.
- MIRD pamphlet No. 20: the effect of model assumptions on kidney dosimetry and response--implications for radionuclide therapy.
- Risks to normal tissues from radionuclide therapy.
- Targeted radionuclide therapy.
- Locoregionally advanced head and neck cancer treated with primary radiotherapy: a comparison of the addition of cetuximab or chemotherapy and the impact of protocol tr...
- Phase II study of palifermin and concurrent chemoradiation in head and neck squamous cell carcinoma.
- Final report of RTOG 9610, a multi-institutional trial of reirradiation and chemotherapy for unresectable recurrent squamous cell carcinoma of the head and neck.
- A method to correct for radioactivity in large vessels that overlap the spine in imaging-based marrow dosimetry of lumbar vertebrae.
- Predictors of distant brain recurrence for patients with newly diagnosed brain metastases treated with stereotactic radiosurgery alone.
- Brief overview of preclinical and clinical studies in the development of intraperitoneal radioimmunotherapy for ovarian cancer.
- Retreatment with yttrium-90 ibritumomab tiuxetan in patients with B-cell non-Hodgkin''s lymphoma.
- Microvessel density >or=60 does not predict for outcome after radiation treatment for locally advanced head and neck squamous cell carcinoma: results of a correlative ...
- Can serum markers be used to predict acute and late toxicity in patients with lung cancer? Analysis of RTOG 91-03.
- Longitudinal evaluation of the oral mucositis weekly questionnaire-head and neck cancer, a patient-reported outcomes questionnaire.
- Multiple myeloma. Clinical practice guidelines in oncology.
- Case report of a patient with primary central nervous system lymphoma treated with radioimmunotherapy.
- Effect of pilocarpine during radiation therapy: results of RTOG 97-09, a phase III randomized study in head and neck cancer patients.
- 166Ho-DOTMP radiation-absorbed dose estimation for skeletal targeted radiotherapy.
- Systemic Targeted Radionuclide Therapy symposium introduction.
- Pretargeted radioimmunotherapy.
- Overview of dosimetry for Systemic Targeted Radionuclide Therapy (STaRT).
- Logistics of therapy with the ibritumomab tiuxetan regimen.
- Ongoing investigations and new uses of radioimmunotherapy in the treatment of non-Hodgkin's lymphoma.
- Summary of systemic targeted radionuclide therapy symposium.
- Clinical development of radioimmunotherapy for B-cell non-Hodgkin's lymphoma.
- Phase I study of 90Y-CC49 monoclonal antibody therapy in patients with advanced non-small cell lung cancer: effect of chelating agents and paclitaxel co-administration.
- Pretargeted radioimmunotherapy (RIT) with a novel anti-TAG-72 fusion protein.
- Blood-based red marrow dosimetry: where's the beef?
- Clinically useful marrow dosimetry for targeted radionuclide therapy.
- Patient-specific dosimetry of pretargeted radioimmunotherapy using CC49 fusion protein in patients with gastrointestinal malignancies.
- Testicular uptake and radiation dose in patients receiving Zevalin and Pretarget CC49Fusion protein.
- Bone marrow dosimetry using blood-based models for radiolabeled antibody therapy: a multiinstitutional comparison.
- Phase 1 trial of a novel anti-CD20 fusion protein in pretargeted radioimmunotherapy for B-cell non-Hodgkin lymphoma.
- P105 as a prognostic indicator in patients irradiated for locally advanced head-and-neck cancer: a clinical/laboratory correlative analysis of RTOG-9003.
- A novel monoclonal antibody design for radioimmunotherapy.
- Phase III quality-of-life study results: impact on patients' quality of life to reducing xerostomia after radiotherapy for head-and-neck cancer--RTOG 97-09.
- Comparison of biodistribution, dosimetry, and outcome from clinical trials of radionuclide-CC49 antibody therapy.
- Comparison of methods for predicting myelotoxicity for non-marrow targeting I-131-antibody therapy.
- Phase 1 trial of combined chemotherapy and reirradiation for recurrent unresectable head and neck cancer.
- A Phase I study of combined modality (90)Yttrium-CC49 intraperitoneal radioimmunotherapy for ovarian cancer.
- Improved prediction of myelotoxicity using a patient-specific imaging dose estimate for non-marrow-targeting (90)Y-antibody therapy.
- Concurrent chemoradiation therapy with cisplatin and paclitaxel for locally advanced non-small cell lung cancer: long-term follow-up of a phase I trial.
- Rationales, evidence, and design considerations for fractionated radioimmunotherapy.
- Model prediction of treatment planning for dose-fractionated radioimmunotherapy.
- Clinical trial design and scoring of radionuclide therapy endpoints: normal organ toxicity and tumor response.
- Radioimmunotherapy of B-cell NHL.
- RTOG 96-10: reirradiation with concurrent hydroxyurea and 5-fluorouracil in patients with squamous cell cancer of the head and neck.
- Intraperitoneal radioimmunochemotherapy of ovarian cancer: a phase I study.
- Phase I study of anti--epidermal growth factor receptor antibody cetuximab in combination with radiation therapy in patients with advanced head and neck cancer.
- Enhanced apoptosis with combination C225/radiation treatment serves as the impetus for clinical investigation in head and neck cancers.
- Clinical radioimmunotherapy.
- Combined modality therapy of A431 human epidermoid cancer using anti-EGFr antibody C225 and radiation.
- Phase II study of interferon-enhanced 131I-labeled high affinity CC49 monoclonal antibody therapy in patients with metastatic prostate cancer.
- A strategy to reduce red marrow dose for intraperitoneal radioimmunotherapy.
- Concomitant chemotherapy and reirradiation as management for recurrent cancer of the head and neck.
- Chimeric antibodies with specificity for tumor antigens: demonstration of in situ localization to tumors after antibody therapy.
- Scleredema of Buschke successfully treated with electron beam therapy.
- Recent progress in radioimmunotherapy for cancer.
- Intraperitoneal radioimmunotherapy of ovarian cancer with 177Lu-CC49: a phase I/II study.
- Correlation of toxicity with treatment parameters for 131I-CC49 radioimmunotherapy in three phase II clinical trials.
- Sucralfate for radiation mucositis: results of a double-blind randomized trial.
- Postsurgical recurrent carcinoma of the cervix: reassessment and results of radiation therapy options.
- Phase II study of dual 131I-labeled monoclonal antibody therapy with interferon in patients with metastatic colorectal cancer.
- Intraperitoneal radioimmunotherapy of ovarian cancer with lutetium-177-CC49.
- Major geometric variations between intracavitary applications in carcinoma of the cervix: high dose rate vs. low dose rate.
- Fractionated radioimmunotherapy of human colon carcinoma xenografts with 131I-labeled monoclonal antibody CC49.
- Initial clinical evaluation of iodine-125-labeled chimeric 17-1A for metastatic colon cancer.
- Major geometric variations between multiple high-dose-rate applications of brachytherapy in cancer of the cervix: frequency and types of variation.
- Conventional four-field pelvic radiotherapy technique without computed tomography-treatment planning in cancer of the cervix: potential geographic miss and its impact ...
- Tumor associated glycoprotein-72 is highly expressed in prostatic adenocarcinomas.
- Treatment of metastatic prostate carcinoma with radiolabeled antibody CC49.
- Conventional four-field pelvic radiotherapy technique without CT treatment planning in cancer of the cervix: potential geographic miss.
- Malignant epidural spinal cord compression associated with a paravertebral mass: its radiotherapeutic outcome on radiosensitivity.
- Direct localization comparison of murine and chimeric B72.3 antibodies in patients with colon cancer.
- A phase I clinical trial of murine monoclonal antibody D612 in patients with metastatic gastrointestinal cancer.
- Dosimetry of solid tumors.
- A phase I study of high-dose cisplatin, prolonged infusion 5-fluorouracil, and concomitant conventional fraction radiation therapy in patients with inoperable squamous...
- Dose fractionation of radiolabeled antibodies in patients with metastatic colon cancer.
- Phase I trial of iodine-131-chimeric B72.3 (human IgG4) in metastatic colorectal cancer.
- Treatment of recurrent head and neck cancer with 5-fluorouracil, hydroxyurea, and reirradiation.
- Pharmacokinetics and immune response of 131I-chimeric mouse/human B72.3 (human gamma 4) monoclonal antibody in humans.
- Expedient set-up of tangential breast fields with a simple gantry attachment.
- Three-port perineal sparing technique.
- Pharmacokinetics, immune response, and biodistribution of iodine-131-labeled chimeric mouse/human IgG1,k 17-1A monoclonal antibody.
Schools
Ohio State University College Of Medicine and Public Health
Med College Va
Doctors Specialties
- Radiation Oncology
Accepted Insurances
- Aetna
- Blue Card PPO
- Dental Blue 100/200/300
- Cigna HMO
- Cigna PPO
- Great West Healthcare-Cigna PPO
- Open Access Plus
- Commercial Insurance Company
- First Health (Coventry Health Care) PPO
- Golden Rule
- Choice Care PPO
- Medicare MCR
- MultiPlan PPO
- Choice Plus POS
- Navigate HMO
- Navigate POS
- Options PPO
- United Healthcare
Awards
- America's Top Doctors
- America's Top Doctors for Cancer
- Whos Who in Medicine and Healthcare
Education
-
The Ohio State University College of Medicine
Hospital
-
University of Alabama Hospital -
Birmingham Veterans Affairs Medical Center -
Children's of Alabama -
Cooper Green Hospital
Drug Facts
| NPI NUMBER | 1083643829 | |
| NPPES Provider LastName | MEREDITH | |
| NPPES Provider FirstName | RUBY | |
| NPPES Provider ZIPCode | 35233 | |
| NPPES Provider State | AL | |
| Specialty Description | Diagnostic Radiology | |
| Total Claim Count | 14.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1083643829 |
| Last Name Of The Provider | MEREDITH |
| First Name Of The Provider | RUBY |
| View All |
Similar Doctors
|
|
Dr. Christopher D. Willey, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. John B. Fiveash, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. John D. Glover, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Olivia C. Barrett, MD |
|
|
Dr. James M. Kamplain, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Caleb R. Dulaney, MD |
|
|
Dr. Lisa C. Klepczyk, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Grant M. Clark, MD
This Doctor is OpenDoctor Recommended.
|